A small cassette enables conditional gene inactivation by CRISPR/Cas9

被引:0
|
作者
Paloma M. Guzzardo
Christina Rashkova
Rodrigo L. dos Santos
Raha Tehrani
Philippe Collin
Tilmann Bürckstümmer
机构
[1] Horizon Genomics GmbH,
[2] Horizon Discovery Ltd,undefined
来源
Scientific Reports | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The availability of CRISPR/Cas9 technology has enabled the rapid establishment of gene knockouts in many cell types and even whole organisms. However, conditional inactivation of essential genes remains a challenge. We devised an approach named DECAI (DEgradation based on Cre-regulated- Artificial Intron). It utilizes a small cassette of just 201 nucleotides that is inserted into the coding exon of a target gene using CRISPR/Cas9 technology and homology-directed repair. As its sequence is derived from an artificial intron, the cassette is removed by the splicing machinery and thus leaves no trace in the “off-state”. Upon activation with Cre recombinase (“on-state”), the intron is crippled and the target gene is disrupted by a series of stop codons. We exemplify the utility of this approach on several non-essential and essential human genes. Clones bearing the conditional knockout cassette are recovered at frequencies above 5% and cassette function can be traced at the genomic DNA and the mRNA level. Importantly, cassette activation leads to loss of gene expression as judged by flow cytometry, Western blot or immunofluorescence. Altogether, this highlights the broad utility of the approach for conditional gene inactivation and suggests that this tool could be used to study the loss-of-function phenotypes of essential genes.
引用
收藏
相关论文
共 50 条
  • [21] Optical Control of CRISPR/Cas9 Gene Editing
    Hemphill, James
    Borchardt, Erin K.
    Brown, Kalyn
    Asokan, Aravind
    Deiters, Alexander
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (17) : 5642 - 5645
  • [22] Spatiotemporal control of CRISPR/Cas9 gene editing
    Chenya Zhuo
    Jiabin Zhang
    Jung-Hwan Lee
    Ju Jiao
    Du Cheng
    Li Liu
    Hae-Won Kim
    Yu Tao
    Mingqiang Li
    Signal Transduction and Targeted Therapy, 6
  • [23] The dawn of the CRISPR/Cas9 gene therapy era
    不详
    LANCET HAEMATOLOGY, 2024, 11 (01): : e1 - e1
  • [24] GENE EDITING IN CHONDROCYTES USING CRISPR/CAS9
    Gibson, G.
    Yang, M.
    OSTEOARTHRITIS AND CARTILAGE, 2016, 24 : S2 - S3
  • [25] CRISPR/Cas9: The new era of gene therapy
    Alotaibi, Amal
    INTERNATIONAL JOURNAL OF ADVANCED AND APPLIED SCIENCES, 2020, 7 (10): : 20 - 29
  • [26] Spatiotemporal control of CRISPR/Cas9 gene editing
    Zhuo, Chenya
    Zhang, Jiabin
    Lee, Jung-Hwan
    Jiao, Ju
    Cheng, Du
    Liu, Li
    Kim, Hae-Won
    Tao, Yu
    Li, Mingqiang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [27] What is CRISPR/Cas9?
    Redman, Melody
    King, Andrew
    Watson, Caroline
    King, David
    ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION, 2016, 101 (04): : 213 - 215
  • [28] The CRISPR/CAS9 world
    Perini, Giovanni
    MOLECULAR CYTOGENETICS, 2017, 10
  • [29] CRISPR/CAS9 Technologies
    Williams, Bart O.
    Warman, Matthew L.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (05) : 883 - 888
  • [30] Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing
    Xiu, Kemao
    Saunders, Laura
    Wen, Luan
    Ruan, Jinxue
    Dong, Ruonan
    Song, Jun
    Yang, Dongshan
    Zhang, Jifeng
    Xu, Jie
    Chen, Y. Eugene
    Ma, Peter X. X.
    CELLS, 2023, 12 (01)